{"disease":{"id":"psma-positive-mcrpc","name":"psma positive mcrpc"},"drugs":{"marketed":[{"drug_id":"lutetium-177lu-vipivotide-tetraxetan","indication_name":"PSMA-positive mCRPC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"Lutetium (177Lu) vipivotide tetraxetan","company_name":"Aaa Usa Novartis","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":45,"revenue":"386","mechanism":"Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells."},{"drug_id":"lutetium-lu-177-vipivotide-tetraxetan","indication_name":"PSMA-positive mCRPC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN","company_name":"","drug_phase":"marketed","molecular_target":"PSMA","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":45,"revenue":null,"mechanism":"Lutetium Lu 177 vipivotide tetraxetan binds to PSMA on prostate cancer cells, delivering radiation that causes DNA damage and cell death."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07226986","title":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":123,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}